| C1 | Time-space cluster investigation using data from a recent infection surveillance system in 5 districts in Namibia, during July 2019 ' February 2020 | E-poster | Epidemiology of HIV in the general population |
| D43 | Timely pediatric regimen optimization at health facilities in Malawi is achievable despite COVID-19 pandemic restrictions with use of a virtual pediatric optimization toolkit and dedicated family ART clinic days | E-poster | Capacity-building initiatives |
| C32 | Three approaches to forecasting potential numbers of dapivirine ring users for HIV prevention among women in sub-Saharan Africa | E-poster | Novel delivery systems (e.g., rings, implants, transdermal systems) |
| D55 | 'This is what I want': qualitative study exploring HIV care intervention options for mobile youth living with HIV (YLWH) in Eastern Africa | E-poster | Qualitative and ethnographic methods in HIV research |
| B28 | Thirty-day hospital readmission rates among North Americans living with HIV, 2005'2015 | E-poster | Other non-communicable diseases |
| B62 | There is no substitute for hard work(ing dolutegravir): outcomes of single drug substitutions among CALHIV shifted to a dolutegravir antiretroviral regimen in Mbeya and Mwanza, Tanzania | E-poster | ARV management strategies in paediatric and adolescent populations |
| D113 | Therapeutical itineraries and coping strategies with sexually transmitted infections among transgender women in Brazil: a qualitative study | E-poster | Access to appropriate healthcare services, including for co-infections and co-morbidities |
| D97 | The value and impact of PrEP expansion depends on underlying epidemiological conditions: an illustration and implications for the HIV epidemic response in the United States | E-poster | Pre-exposure prophylaxis |
| B2 | The VACS index predicts five year mortality among people living with HIV In Thailand | E-poster | Morbidity, mortality and life expectancy |
| B32 | The safety and efficacy of maintenance with doravirine/lamivudine/tenofovir through 192 weeks in adults with HIV-1: results from the DRIVE-AHEAD clinical trial | E-poster | ART in first- and second-line therapies |